Teva receives license to three patents covering oxycodone dosage forms

Purdue Pharma L.P. et al. v. Teva Pharmaceuticals USA, Inc.; Purdue Pharma L.P. et al. v. Teva Pharmaceuticals USA, Inc.

Case Number: 1:13-cv-04606-SHS; 1:14-cv-02357-SHS

Teva settled with plaintiffs in two matters concerning abuse-proofing pharmaceutical dosage forms. One settlement covered U.S. Patents Nos. Patents U.S. Patent No. 8,309,060 (“Abuse-proofed dosage form”) and 8,337,888 (“Pharmaceutical formulation containing gelling agent”). The second settlement covered U.S. Patent No. 6,488,963 (“Hot-melt extrudable pharmaceutical formulation”). Teva acknowledged the patents’ validity and enforceability, and further agreed that, but for an undisclosed license agreement, its oxycodone products would infringe the patents.

The articles on our Website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice.